General Information of the Compound
| Compound ID |
CP0538656
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
5-methoxy-N-[(4-methoxyphenyl)methyl]-1H-indole-2-sulfonamide
Show/Hide
|
||||||||||||||||||
| Synonyms |
N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 1
PMID26161824-Compound-186
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C17H18N2O4S
|
||||||||||||||||||
| Molecular Weight |
346.408
|
||||||||||||||||||
| Canonical SMILES |
COc1ccc(CNS(=O)(=O)c2cc3cc(OC)ccc3[nH]2)cc1
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C17H18N2O4S/c1-22-14-5-3-12(4-6-14)11-18-24(20,21)17-10-13-9-15(23-2)7-8-16(13)19-17/h3-10,18-19H,11H2,1-2H3
Show/Hide
|
||||||||||||||||||
| InChIKey |
ZYAIUNMZKGHCRV-UHFFFAOYSA-N
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
Map of Molecular Bioactivity Related to the Compound
|
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Compound
Clinical Information about the Compound
Drug 1 ( N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 1 )
| Drug Name | N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 1 | ||
|---|---|---|---|
| Company | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN GREIG, lain Robert ROSS, Ruth Alexandra PERTWEE, Roger Guy TREMBLEAU, Laurent Alain Claude ABDEL-RAHMAN, Mostafa Hamed BAILLIE, Gemma Louise | ||
| Indication | |||
| Target(s) | |||